Profiles of Coagulation and Fibrinolysis Activation-Associated Molecular Markers of Atypical Hemolytic Uremic Syndrome in the Acute Phase.

Published on Apr 1, 2020in Journal of Atherosclerosis and Thrombosis4.928
路 DOI :10.5551/JAT.49494
Satoko Sakurai3
Estimated H-index: 3
(UTokyo: University of Tokyo),
Hideki Kato24
Estimated H-index: 24
(UTokyo: University of Tokyo)
+ 7 AuthorsMasaomi Nangaku84
Estimated H-index: 84
(UTokyo: University of Tokyo)
Sources
Abstract
AIM: Atypical hemolytic uremic syndrome (aHUS), characterized by thrombotic microangiopathy (TMA), is a genetic, life-threatening disease which needs many differential diagnoses. This study aimed to reveal coagulation and fibrinolysis profiles in aHUS and secondary TMA patients. Furthermore, we investigated whether aHUS patients progress to, and meet, disseminated intravascular coagulation (DIC) criteria. METHODS: The acute phase samples were available in 15 aHUS and 20 secondary TMA patients. We measured PT-ratio, activated partial thromboplastin time (APTT), fibrinogen, fibrin degradation product (FDP), fibrin monomer complex (FMC), antithrombin (AT), plasmin-伪2 plasmin inhibitor complex (PIC), and von Willebrand factor antigen (VWF:Ag). We examined and compared these tests among aHUS, secondary TMA patients, and healthy volunteer (HV), and evaluated whether patients with aHUS and secondary TMA met DIC criteria. RESULTS: PT-ratio, APTT, FDP, FMC and PIC in patients with aHUS and secondary TMA were higher than those in HV. Fibrinogen and AT showed no significant difference among three groups. VWF:Ag was higher in only aHUS patients. No tests showed significant difference between aHUS and secondary TMA patients. Three aHUS patients out of 15 met DIC criteria. CONCLUSION: We revealed the profiles and distributions of coagulation and fibrinolysis tests of aHUS and secondary TMA patients. All tests were enhanced compared to HV; however, our results showed the no specificities in distinguishing aHUS from secondary TMA patients. We also clarified that some aHUS patients fulfilled DIC diagnostic criteria, indicating that DIC itself cannot be an exclusion criterion of aHUS.
馃摉 Papers frequently viewed together
201423.63Blood
21 Authors (Doyeun Oh, ..., Yeo-Kyeoung Kim)
References40
Newest
#1Yoko Yoshida (UTokyo: University of Tokyo)H-Index: 16
#2Hideki Kato (UTokyo: University of Tokyo)H-Index: 24
Last. Masaomi Nangaku (UTokyo: University of Tokyo)H-Index: 84
view all 4 authors...
Atypical hemolytic uremic syndrome (aHUS) is a type of thrombotic microangiopathy (TMA) defined by thrombocytopenia, microangiopathic hemolytic anemia, and renal failure. aHUS is caused by uncontrolled complement activation in the alternative pathway (AP). A variety of genetic defects in complement-related factors or acquired autoantibodies to the complement regulators have been found in 50 to 60% of all cases. Recently, however, the classification and diagnosis of aHUS are becoming more complic...
Source
#1Madoka Fujisawa (UTokyo: University of Tokyo)H-Index: 3
#2Hideki Kato (UTokyo: University of Tokyo)H-Index: 24
Last. Masaomi Nangaku (UTokyo: University of Tokyo)H-Index: 84
view all 13 authors...
Background Atypical hemolytic uremic syndrome (aHUS) is caused by complement overactivation, and its presentation and prognosis differ according to the underlying molecular defects. The aim of this study was to characterize the genetic backgrounds of aHUS patients in Japan and to elucidate the associations between their genetic backgrounds, clinical findings, and outcomes.
Source
A typical hemolytic uremic syndrome (aHUS) presents similarly to thrombotic thrombocytopenic purpura (TTP) and other causes or conditions with thrombotic microangiopathy (TMA), such as disseminated intravascular coagulation or sepsis. Similarity in clinical presentation may hinder diagnosis and optimal treatment selection in the urgent setting in the ICU. However, there is currently no consensus on the diagnosis or treatment of aHUS for ICU specialists. This review aims to summarize available da...
Source
#1T. Sakari Jokiranta (HYKS: Helsinki University Central Hospital)H-Index: 41
Hemolytic uremic syndrome (HUS) is a thrombotic microangiopathy characterized by intravascular hemolysis, thrombocytopenia, and acute kidney failure. HUS is usually categorized as typical, caused by Shiga toxin鈥損roducing Escherichia coli (STEC) infection, as atypical HUS (aHUS), usually caused by uncontrolled complement activation, or as secondary HUS with a coexisting disease. In recent years, a general understanding of the pathogenetic mechanisms driving HUS has increased. Typical HUS (ie, STE...
Source
#1Teresa CaveroH-Index: 10
#2Cristina RabascoH-Index: 7
Last. Manuel PragaH-Index: 62
view all 28 authors...
Work in this report was funded by the Instituto de Salud Carlos III: REDinREN (RD 016/009 Feder Funds), the Fondo de Investigaciones Sanitarias (13/02502 and ICI14/00350), the Ministerio de Economia y Competitividad (SAF2015-66287R) and the Autonomous Region of Madrid (S2010/BMD-2316; Grupo de Investigacion Complemento-CM). SRdeC is funded by the Seventh Framework Programme European Union Project EURenOmics (305608)
Source
#1Timothy H.J. Goodship (Newcastle University)H-Index: 66
#2H. Terence Cook (Imperial College London)H-Index: 72
Last. Santiago Rodr铆guez de C贸rdoba (CSIC: Spanish National Research Council)H-Index: 68
view all 53 authors...
In both atypical hemolytic uremic syndrome (aHUS) and C3 glomerulopathy (C3G) complement plays a primary role in disease pathogenesis. Herein we report the outcome of a 2015 Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference where key issues in the management of these 2 diseases were considered by a global panel of experts. Areas addressed included renal pathology, clinical phenotype and assessment, genetic drivers of disease, acquired drivers of disease, and treatment st...
Source
#1Tomohiro Abe (Saitama Medical University)H-Index: 1
#2Akira SasakiH-Index: 1
Last. Hidenobu OchiaiH-Index: 15
view all 5 authors...
AbstractSecondary thrombotic microangiopathies (TMAs) are induced by several underlying conditions; most are resolved by treating background disease. Eculizumab is a human monoclonal antibody that blocks the final stage of the complement system and effectively treats atypical hemolytic uremic syndro
Source
#1Jeffrey Laurence (NewYork鈥揚resbyterian Hospital)H-Index: 46
#2Hermann Haller (MHH: Hannover Medical School)H-Index: 114
Last. Santiago Rodr铆guez de C贸rdoba (CSIC: Spanish National Research Council)H-Index: 68
view all 6 authors...
Atypical hemolytic uremic syndrome (aHUS), a thrombotic microangiopathy (TMA), is a rare, life-threatening, systemic disease. When unrecognized or inappropriately treated, aHUS has a high degree of morbidity and mortality. aHUS results from chronic, uncontrolled activity of the alternative complement pathway, which activates platelets and damages the endothelium. Two-thirds of aHUS cases are associated with an identifiable complement-activating condition. aHUS is clinically very similar to the o...
#1Hidesaku Asakura (Kanazawa University)H-Index: 31
#2Hoyu TakahashiH-Index: 29
Last. Hideo Wada (Mie University)H-Index: 61
view all 8 authors...
Disseminated intravascular coagulation (DIC) is a serious disease that, in the presence of underlying disease, causes persistent, generalized, marked coagulation activation. Early treatment based on an appropriate diagnosis is very important for improving patients鈥 prognosis, to which end diagnostic criteria play a key role. Several criteria have been proposed, but each has its strengths and weaknesses, and improved criteria are needed. Widespread use of coagulofibrinolytic markers has elucidate...
Source
#1Hideki Kato (UTokyo: University of Tokyo)H-Index: 24
#2Masaomi Nangaku (UTokyo: University of Tokyo)H-Index: 84
Last. Shoji Kagami (University of Tokushima)H-Index: 38
view all 17 authors...
Atypical hemolytic uremic syndrome (aHUS) is a rare disease characterized by the triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury. In 2013, we developed diagnostic criteria to enable early diagnosis and timely initiation of appropriate treatment for aHUS. Recent clinical and molecular findings have resulted in several proposed classifications and definitions of thrombotic microangiopathy and aHUS. Based on recent advances in this field and the emerging intern...
Source
Cited By5
Newest
#1Sofia Menotti (University of Verona)
#2Martino Donini (University of Verona)
Last. Oliviero Olivieri (University of Verona)H-Index: 66
view all 15 authors...
Source
Quetiapine has been reported to cause immune-mediated thrombotic microangiopathy (TMA), although few cases have been reported thus far. A 71-year-old man with autosomal dominant polycystic kidney disease on maintenance dialysis was hospitalized with a hemorrhagic basal ganglia stroke, and was treated with 25聽mg quetiapine for delirium from day 4 of admission. There was no worsening of consciousness, fever, diarrhea, or elevated blood pressure during the hospitalization. Gingival bleeding appeare...
Source
#1Junji Shimizu (Shiga University of Medical Science)H-Index: 2
#2Kazunori Fujino (Shiga University of Medical Science)H-Index: 10
Last. Yutaka Eguchi (Shiga University of Medical Science)H-Index: 23
view all 6 authors...
Aim The complement system is important for defending against pathogens, however, excessive complement activation is associated with a poor prognosis and organ dysfunction in sepsis. Complement factor H (CFH) acts to prevent excessive complement activation and damage to the self through the regulation of the complement alternative pathway. We investigated the association between plasma CFH levels on admission to the intensive care unit (ICU) and 90-day mortality, severity scores, and organ dysfun...
Source
#1Monica A. Bray (BCM: Baylor College of Medicine)H-Index: 2
#2Sarah E. Sartain (BCM: Baylor College of Medicine)H-Index: 8
Last. Rolando E. Rumbaut (BCM: Baylor College of Medicine)H-Index: 29
view all 4 authors...
Abstract A significant amount of clinical and research interest in thrombosis is focused on large vessels (e.g., stroke, myocardial infarction, deep venous thrombosis, etc.); however, thrombosis is often present in the microcirculation in a variety of significant human diseases, such as disseminated intravascular coagulation, thrombotic microangiopathy, sickle cell disease, and others. Further, microvascular thrombosis has recently been demonstrated in patients with COVID-19, and has been propos...
Source
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.